Contract analysis

I. Executive Summary The purpose of this memorandum is to analyze the legal framework governing the arm's-length royalty rate applicable to the intercompany license of legacy pharmaceutical intellectual property ("IP") from Penterra Pharmaceuticals Corp. ("PPC") to Penterra Biopharma International DAC ("PBI"), and to assess the defensibility of PPC's 4.5% royalty rate under Section 482 of the Internal Revenue Code of

II. Factual Background A. The Parties and Corporate Structure Penterra Pharmaceuticals Corp. ("PPC"). PPC is a corporation organized under the laws of the State of Delaware and publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on oncol

III. Applicable Legal Framework A. IRC § 482 — General Authority IRC § 482 provides the Commissioner of Internal Revenue with broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses that are "owned or controlled directly or indirectly by the same interests" if the Commissioner determines that such distribution, appor

1. Overview of Available Methods. Treas. Reg. § 1.482-4(a) specifies the methods available for determining the arm's-length consideration for controlled transfers of intangible property. The regulations define "intangible property" broadly to include patents, inventions, formulae, processes, designs, patterns, know-how, copyrights, literary or artistic compositions, trademarks, trade names, franchises, licenses, cont

2. The Comparable Uncontrolled Transaction (CUT) Method — § 1.482-4(c). The CUT method evaluates whether the amount charged in a controlled transfer of intangible property is arm's length by reference to the amount charged in a comparable uncontrolled transaction. Treas. Reg. § 1.482-4(c)(1) provides the general rule that the CUT method evaluates the arm's-length charge for a controlled transfer of intangible propert

3. Comparability Factors Under § 1.482-4(c)(2). The regulations provide both general and specific comparability factors that must be considered in evaluating whether an uncontrolled transaction is comparable to the controlled transaction under review. General Comparability Factors. Treas. Reg. § 1.482-1(d)(3) sets forth general comparability factors applicable to all methods, including: (i) functions performed by the

IV. Analysis of PPC's 4.5% Royalty Rate Under the CUT Method A. Selection and Application of the CUT Method as Best Method As discussed in Section III.C above, the CUT method is selected as the best method for testing the arm's-length character of the 4.5% royalty rate under the Legacy License. The rationale for this selection rests on two pillars: the availability of sufficiently comparable uncontrolled pharmaceutic

1. Declining Product Lifecycle. The most significant comparability factor favoring PPC's 4.5% royalty rate is the declining product lifecycle of the legacy compounds. Non-Americas net sales dropped from $814.6 million in 2017 to $624.1 million in 2020, a decline of approximately 23.4% over the four-year examination period. This decline trajectory is consistent with the natural lifecycle of branded pharmaceutical prod

2. PBI's Substantive Functions and Risk-Bearing. A second critical factor favoring PPC's rate is PBI's status as a substantive, risk-bearing licensee — not a passive recipient of IP rights. The arm's-length standard recognizes that, in an uncontrolled transaction, a licensee that performs significant value-adding functions and bears substantial risks will negotiate a lower royalty rate than a licensee that merely dis

3. Exclusivity and Geographic Scope. The Legacy License grants PBI exclusive rights to commercialize the licensed compounds in the non-Americas territory. While exclusivity is a valuable right — and generally supports a higher royalty rate compared to a non-exclusive license — the geographic scope and market characteristics of the Licensed Territory introduce countervailing factors that moderate the value of the excl

4. Absence of Sub-licensing Rights. Under the terms of the Legacy License, PBI does not have the right to sub-license the licensed IP to third parties without PPC's prior written consent. This restriction limits PBI's ability to exploit the licensed IP through third-party arrangements and reduces the flexibility and value of the license compared to a license that includes unrestricted sub-licensing rights. In the com